|
is A Reality Check –Targeting the PD-1/PD-L1 axis in the treatment of Acute Myeloid Leukemia |
09/29/2022 - 12:00pm to 1:00pm |
|
Hematology/Oncology Fellows Case Conference |
10/13/2022 - 12:00pm to 1:00pm |
|
Social Determinants in Sickle Cell Disease & Tocilizumab for Acute Chest and Evaluating the Effect of Steroid Sparing Immunosuppressive Agents on Tumor Outcome |
11/03/2022 - 12:00pm to 1:00pm |
|
Leveraging a Novel Combination Strategy of Targeted MEK Inhibition with Azacitidine for Patients with High-Risk Chronic Myeloid Neoplasms |
12/08/2022 - 12:00pm to 1:00pm |
|
Hematology/Oncology Fellows Case Conference |
03/30/2023 - 12:00pm to 1:00pm |
|
Circulating Tumor DNA in Stage II Colon Cancer Management |
04/13/2023 - 12:00pm to 1:00pm |
|
Hematology/Oncology Fellows Case Conference |
04/27/2023 - 12:00pm to 1:00pm |
|
Hematology/Oncology Fellows Case Conference |
05/11/2023 - 12:00pm to 1:00pm |
|
Annual Fellow QI/Safety Presentations |
06/08/2023 - 12:00pm to 1:00pm |
|
Hematology/Oncology Fellows Case Conference |
06/23/2023 - 12:00pm to 1:00pm |
Facebook
Twitter
LinkedIn
Forward